[go: up one dir, main page]

GB9524942D0 - Drug therapy - Google Patents

Drug therapy

Info

Publication number
GB9524942D0
GB9524942D0 GBGB9524942.1A GB9524942A GB9524942D0 GB 9524942 D0 GB9524942 D0 GB 9524942D0 GB 9524942 A GB9524942 A GB 9524942A GB 9524942 D0 GB9524942 D0 GB 9524942D0
Authority
GB
United Kingdom
Prior art keywords
drug therapy
therapy
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9524942.1A
Inventor
Tariq Khan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aepact Ltd
Original Assignee
Aepact Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aepact Ltd filed Critical Aepact Ltd
Priority to GBGB9524942.1A priority Critical patent/GB9524942D0/en
Publication of GB9524942D0 publication Critical patent/GB9524942D0/en
Priority to PCT/GB1996/003000 priority patent/WO1997020580A1/en
Priority to CA002239203A priority patent/CA2239203A1/en
Priority to JP9521082A priority patent/JP2000502071A/en
Priority to EP96940685A priority patent/EP0865298A1/en
Pending legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6891Pre-targeting systems involving an antibody for targeting specific cells
    • A61K47/6899Antibody-Directed Enzyme Prodrug Therapy [ADEPT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C333/00Derivatives of thiocarbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C333/02Monothiocarbamic acids; Derivatives thereof
    • C07C333/04Monothiocarbamic acids; Derivatives thereof having nitrogen atoms of thiocarbamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/38One sulfur atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nanotechnology (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Molecular Biology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
GBGB9524942.1A 1995-12-06 1995-12-06 Drug therapy Pending GB9524942D0 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
GBGB9524942.1A GB9524942D0 (en) 1995-12-06 1995-12-06 Drug therapy
PCT/GB1996/003000 WO1997020580A1 (en) 1995-12-06 1996-12-06 Drug therapy
CA002239203A CA2239203A1 (en) 1995-12-06 1996-12-06 Drug therapy
JP9521082A JP2000502071A (en) 1995-12-06 1996-12-06 Drug therapy
EP96940685A EP0865298A1 (en) 1995-12-06 1996-12-06 Drug therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9524942.1A GB9524942D0 (en) 1995-12-06 1995-12-06 Drug therapy

Publications (1)

Publication Number Publication Date
GB9524942D0 true GB9524942D0 (en) 1996-02-07

Family

ID=10784998

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9524942.1A Pending GB9524942D0 (en) 1995-12-06 1995-12-06 Drug therapy

Country Status (5)

Country Link
EP (1) EP0865298A1 (en)
JP (1) JP2000502071A (en)
CA (1) CA2239203A1 (en)
GB (1) GB9524942D0 (en)
WO (1) WO1997020580A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9712370D0 (en) 1997-06-14 1997-08-13 Aepact Ltd Therapeutic systems
ATE499115T1 (en) * 1998-09-18 2011-03-15 Immunomedics Inc ANTIBODIES REFERRED ENZYME PRODRUG THERAPY WITH GLUCURONIDASE
IL126732A0 (en) * 1998-10-23 1999-08-17 Intelligene Ltd Pro drug
GB0916749D0 (en) * 2009-09-23 2009-11-04 Mologic Ltd Peptide cleaning agents
GB201308363D0 (en) 2013-05-09 2013-06-19 Bagshawe Kenneth D Tumour therapy

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8705477D0 (en) * 1987-03-09 1987-04-15 Carlton Med Prod Drug delivery systems
GB9200417D0 (en) * 1992-01-09 1992-02-26 Bagshawe Kenneth D Cytotoxic drug therapy

Also Published As

Publication number Publication date
CA2239203A1 (en) 1997-06-12
WO1997020580A1 (en) 1997-06-12
EP0865298A1 (en) 1998-09-23
JP2000502071A (en) 2000-02-22

Similar Documents

Publication Publication Date Title
GB9505491D0 (en) Therapeutic agents
GB9523244D0 (en) Therapeutic agents
GB9513118D0 (en) Therapeutic agents
GB9513117D0 (en) Therapeutic agents
GB9505492D0 (en) Therapeutic agents
GB9507291D0 (en) Therapeutic agents
GB9519563D0 (en) Therapeutic agents
GB9507348D0 (en) Therapeutic agents
GB9500580D0 (en) Therapeutic agents
GB9501865D0 (en) Therapeutic agents
GB9523243D0 (en) Therapeutic agents
GB9513467D0 (en) Therapeutic agents
GB9524942D0 (en) Drug therapy
GB9521781D0 (en) Therapeutic agents
GB9522495D0 (en) Therapeutic agents
GB9523065D0 (en) Therapeutic agents
GB9510223D0 (en) Therapeutic agent
GB9519558D0 (en) Therapeutic agents
GB9520731D0 (en) Therapeutic agents
GB9523064D0 (en) Therapeutic agents
GB9522372D0 (en) Therapeutic agents
GB9503377D0 (en) Therapeutic agents
GB9507224D0 (en) Therapeutic agents
GB9521347D0 (en) Therapeutic agents
PL310059A1 (en) Therapeutic oinment

Legal Events

Date Code Title Description
730 Substitution of applicants allowed (sect. 30/1977)
730 Substitution of applicants allowed (sect. 30/1977)